highperformr logo

Agios Pharmaceuticals's Overview

Total employees614
HeadquartersCambridge
Founded2008

Agios Pharmaceuticals is a biopharmaceutical company dedicated to harnessing scientific leadership in cellular metabolism to create life-changing therapies for patients with genetically defined diseases. Their focus is on developing and commercializing novel treatments that address the underlying metabolic dysregulation in these conditions. Agios is known for its commitment to rigorous science, patient advocacy, and a deep understanding of disease biology. Their lead product, PYRUKYND® (mitapivat), is approved for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, with ongoing research into its potential for other rare hematologic disorders and conditions.

Where is Agios Pharmaceuticals's Headquarters?

Agios Pharmaceuticals officeAgios Pharmaceuticals officeAgios Pharmaceuticals officeAgios Pharmaceuticals office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the central hub for Agios's research and development, corporate operations, strategic planning, commercial activities, and administrative functions.

Notable Features:

Modern laboratory and office facilities designed to foster cutting-edge scientific research, collaboration, and innovation, situated within the dynamic Kendall Square/Central Square biotech ecosystem.

Work Culture:

Agios cultivates a patient-focused, science-driven, and collaborative work environment. The culture emphasizes innovation, integrity, respect, and a commitment to making a meaningful impact on patients' lives. There is a strong focus on employee growth and development.

HQ Significance:

Its location in Cambridge, MA, places Agios at the epicenter of the global biotechnology industry, providing unparalleled access to leading academic institutions, research talent, potential partners, and a vibrant scientific community.

Values Reflected in HQ: The headquarters reflects Agios's core values through its investment in state-of-the-art research facilities (commitment to science and innovation), collaborative workspaces (teamwork), and its strategic location aimed at accelerating therapeutic development (patient focus).

Location:

Agios Pharmaceuticals' primary operations are centralized at its Cambridge, MA headquarters. From this hub, the company manages its global research programs, clinical trials, regulatory interactions, and commercialization strategies. While they may not maintain numerous physical international offices, their therapies and research initiatives have a global reach, impacting patients and collaborating with researchers and healthcare providers worldwide. Their commercial product, PYRUKYND®, is being developed and commercialized for global markets where approved.

Street Address:

88 Sidney Street

City:

Cambridge

State/Province:

MA

Country:

USA

Agios Pharmaceuticals's Global Presence

Buying Intent Signals for Agios Pharmaceuticals

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Agios Pharmaceuticals

As of April 2025, Agios Pharmaceuticals' leadership includes:

Brian Goff - Chief Executive Officer
Sarah Gheuens, M.D., Ph.D. - Chief Medical Officer & Head of R&D
Cecilia Jones - Chief Financial Officer
Richa Poddar - Chief Commercial Officer
James K. Dentzer - Chief People & Administrative Officer
David R. Biondo - General Counsel and Corporate Secretary
Adam Crystal, Ph.D. - Senior Vice President, Head of Discovery
Jessica St. Peter - Senior Vice President, Head of Late-Stage Development

Investors of Agios Pharmaceuticals

Agios Pharmaceuticals has been backed by several prominent investors over the years, including:

The Vanguard Group, Inc.
BlackRock, Inc.
FMR LLC (Fidelity Management & Research)
State Street Corporation
Artal Group S.A.
Price (T. Rowe) Associates Inc

Executive New Hires/Exits in the Last 12 Months

Hire3
Exits1

Agios Pharmaceuticals has seen key leadership appointments in the past year, including a new CEO, a new Chief People & Administrative Officer, and a new General Counsel, signaling a refreshed leadership team focused on its strategic priorities in genetically defined diseases.

Departures

Jackie Fouse, Ph.D., Jackie Fouse transitioned out of her role as CEO.

New Appointments:

Brian Goff, Brian Goff appointed as new Chief Executive Officer.
James K. Dentzer, James K. Dentzer appointed as new Chief People & Administrative Officer.
David R. Biondo, David R. Biondo appointed as new General Counsel and Corporate Secretary.

Technology (Tech Stack) used by Agios Pharmaceuticals

Discover the tools Agios Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Agios Pharmaceuticals Email Formats and Examples

Agios Pharmaceuticals primarily uses the 'first.last' email format. Understanding this common structure can be helpful for professional communication.

first.last@agios.com

Format

jane.doe@agios.com

Example

95%

Success rate

News and media

Agios PharmaceuticalsMay 7, 2024

Agios Pharmaceuticals Reports First Quarter 2024 Financial Results

Agios announced its financial results for Q1 2024, highlighting PYRUKYND® net revenue and progress in its clinical development programs for mitapivat in thalassemia and sickle cell disease....more

Agios PharmaceuticalsApril 29, 2024

Agios Pharmaceuticals Appoints David R. Biondo as General Counsel and Corporate Secretary

Agios announced the appointment of David R. Biondo as its new General Counsel and Corporate Secretary, effective May 13, 2024....more

Agios PharmaceuticalsMarch 11, 2024

Agios Pharmaceuticals Appoints James K. Dentzer as Chief People and Administrative Officer

Agios announced the appointment of James K. Dentzer as Chief People and Administrative Officer, effective March 18, 2024....more

Agios PharmaceuticalsFebruary 15, 2024

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Agios provided a business update and reported financial results for Q4 and full year 2023, emphasizing achievements in its PYRUKYND® franchise and pipeline advancements....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Agios Pharmaceuticals, are just a search away.